DLL3 and small cell lung carcinoma: While its role in promoting SCLC progression via epithelial-mesenchymal transition (EMT) regulation has been proposed (27), clinical studies reveal no correlation between DLL3/ASCL1 expression and survival outcomes in limited- or extensive-stage SCLC (27, 56, 131).